Clinical Trials
0
0 active
Approvals
0
Total approvals
Agencies
0
Regulatory bodies
Founded
N/A
No trial phase data available
No trial data available
No trial data available
No approval data available
- The global nucleic acid therapeutics contract manufacturing market is projected to grow from $9.85 billion in 2024 to $33.84 billion by 2033, representing a CAGR of 15.14%. - Record-high outsourcing levels drive market expansion, with 82.6% of cell and gene therapy companies now outsourcing at least part of their biologics manufacturing. - Rising demand for mRNA and gene therapies, combined with technological manufacturing advancements and regulatory support, fuels the market's rapid growth trajectory.
- D3 Bio completed a $108 million Series B financing round backed by IDG Capital, SongQing Capital, and existing investors including WuXi AppTec's Corporate Venture Fund and Temasek. - The funding will primarily support global Phase III pivotal trials for elisrasib (D3S 001), a KRAS G12C inhibitor, as both monotherapy and combination therapy for KRAS G12C-mutant cancers. - The clinical program is planned to span multiple geographies including the United States, China, and European Union to support global regulatory submissions. - Additional proceeds will advance D3 Bio's broader pipeline of targeted therapies and immuno-oncology candidates with first-in-class or best-in-class potential.
- Onepot AI raised $13 million in funding to address pharmaceutical synthesis bottlenecks that prevent promising drug compounds from being tested due to manufacturing complexity. - The startup's AI-powered synthesis lab POT-1 features "Phil," an AI organic chemist that compresses compound synthesis from months to days for biotech and pharma partners. - The company aims to rebuild small molecule synthesis capabilities in the United States while expanding the design space for drug discovery through AI-driven chemistry optimization.
- NEOM has signed a strategic memorandum of understanding with WuXi AppTec to explore localization of pharmaceutical research, development and manufacturing capabilities in Saudi Arabia. - The partnership aims to create world-class CRDMO facilities at Oxagon, NEOM's advanced manufacturing city, supporting Saudi Arabia's economic diversification and biotechnology ambitions. - This collaboration represents a significant step forward in advancing the Kingdom's National Biotech Strategy as part of Saudi Vision 2030. - The agreement leverages WuXi AppTec's decades of biopharmaceutical innovation experience with NEOM's state-of-the-art clean manufacturing infrastructure to serve regional and global markets.
- Revium Rx has submitted a clinical trial application to the Israeli Ministry of Health for Nano-Mupirocin, targeting first-in-human studies in early 2026. - The novel nano-liposomal formulation aims to overcome mupirocin's blood instability, enabling systemic treatment of multidrug-resistant pathogens including MRSA, VRE, and ceftriaxone-resistant gonorrhea. - MRSA alone was responsible for approximately 130,000 deaths in 2021, highlighting the urgent medical need for new systemic antibiotics. - The global antimicrobial resistance therapeutics market is projected to grow from USD 8.7 billion in 2023 to over USD 12.5 billion by 2030.
- The BIOSECURE Act has re-emerged in Congress through a bipartisan amendment to the National Defense Authorization Act of 2026, after failing to pass in 2024. - The revised version removes specific company names like WuXi AppTec and instead uses broader criteria based on the Department of Defense's List of Chinese Military Companies. - The legislation aims to prohibit federal agencies from contracting with Chinese biotechnology companies deemed to pose national security risks, with potential significant impacts on pharmaceutical supply chains.
• The U.S. healthcare contract research organization market is expected to grow from $15.01 billion in 2025 to $29.68 billion by 2034, driven by increasing R&D investments and technological advancements. • Artificial intelligence integration is revolutionizing CRO operations through enhanced clinical trial design, automated data management, and improved patient recruitment, significantly boosting efficiency and productivity. • The preclinical CRO segment is projected to reach $4.66 billion by 2034, with an 8.2% CAGR, as pharmaceutical companies increasingly outsource specialized research services to reduce costs and accelerate drug development.
• President Trump's tariff policies targeting China, with potential expansion to Canada, Mexico, UK, and EU, are poised to significantly impact pharmaceutical manufacturing and clinical trial costs in the US. • With China currently producing 80% of US pharmaceutical APIs and half of generic drugs, the tariffs could force a major restructuring of drug manufacturing supply chains and increase clinical trial expenses. • The BIOSECURE Act, combined with new tariffs, may accelerate the shift of manufacturing away from China, potentially towards India or domestic US facilities, though capacity and cost challenges remain significant.
• WuXi Biologics has agreed to sell its Dundalk, Ireland vaccine manufacturing facility to MSD for $500 million, with the deal expected to close in first half of 2025. • The sale comes as WuXi Biologics divests Western assets due to the looming US Biosecure Act, which aims to restrict Chinese companies' access to US funding and collaborations. • MSD plans to expand the facility's workforce by adding 150 employees by year-end, building upon the existing 200-person team at the state-of-the-art manufacturing site.
• The global clinical trial outsourcing market is projected to grow from $43.1 billion in 2025 to $91.2 billion by 2034, representing a robust CAGR of 7.46% as pharmaceutical companies increasingly rely on CROs to streamline research processes. • Advanced technologies including AI, machine learning, and blockchain are transforming clinical trial management, enhancing efficiency and accelerating drug approvals while creating new opportunities for market participants. • North America dominates the market due to its strong pharmaceutical industry and favorable regulatory environment, while Asia-Pacific is emerging as a high-growth region offering cost advantages and large patient populations.
